RxDoctor Payments Data

Brandon Weeks, DO

Family Medicine · Plaquemine, LANPI 1366735748

Payments from drug & device makers

$13,047in general payments, 2019–2025

Across 42 payments — averaging $310.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$13K
  • Pfizer$66
  • Esperion Therapeutics, Inc.$40
  • Eisai Inc.$24
  • Xeris Pharmaceuticals, Inc.$23
  • GSK$19
  • plus $17 from 1 others

What the payments were for

  • Speaking & faculty fees$10,11077%
  • Travel & lodging$1,84714%
  • Food & beverage$1,0908%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,047 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$17,463
Medicare patients
102
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide67$89,187
JardianceEmpagliflozin69$88,031
OzempicSemaglutide74$84,699
MounjaroTirzepatide48$63,076
EliquisApixaban65$61,354
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$46,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,711
FarxigaDapagliflozin Propanediol14$12,016
Spiriva HandihalerTiotropium Bromide13$10,495
JanuviaSitagliptin Phosphate15$10,205
Tresiba Flextouch U-100Insulin Degludec14$5,812
Arnuity ElliptaFluticasone Furoate12$3,706
Atorvastatin Calcium535$3,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,020
Gabapentin148$2,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$61,35465 claims
GileadGenvoya$12,860$46,38812 claims
GSKTrelegy Ellipta, Arnuity Ellipta$19$16,41725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Plaquemine

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →